-
Successful pill-taking is an important component for women who use oral contraceptives (OCs). Inconsistent use and method discontinuation are estimated to account for approximately 20% of the annual 3.5 million annual unintended pregnancies in the United States.
-
A quick check of your next patients file shows that she is returning for yet another round of treatment for trichomoniasis. The infection is not responding to standard metronidazole therapy. What is your next move?
-
Your next patient says she has a vaginal discharge. A closer examination reveals a white, noninflammatory discharge that smoothly coats the vaginal walls. What is your next step?
-
Double up on your efforts to detect syphilis. Syphilis rates in the United States rose in 2002 for the second consecutive year, following a decade-long decline that resulted in an all-time low in 2000, according to new data from the Atlanta-based Centers for Disease Control and Prevention (CDC).1
-
When it comes to emergency contraception (EC), are you impeding access to women who might need it?
-
The most comprehensive analysis of U.S. HIV cases completed to date reveals that new HIV diagnoses in 29 states increased in 2002, according to the Centers for Disease Control and Prevention (CDC).
-
Put syphilis testing on your radar screen: Updated guidelines from the U.S. Preventive Services Task Force (USPSTF) recommend that health care providers perform syphilis screening on pregnant women and people who are at high risk for syphilis infection.
-
Which drugs might impact the efficacy of the birth control pill? Comments are offered by Andrew Kaunitz, MD, professor and assistant chair in the obstetrics and gynecology department at the University of Florida Health Science Center/Jacksonville, and Susan Wysocki, RNC, NP, president and chief executive officer of the National Association of Nurse Practitioners in Womens Health.
-
If women could directly access hormonal contraception in pharmacies without a prescription, would they be interested in doing so, provided that pharmacists screen for the methods? A new survey indicates they would.
-
Your next patient is a 17-year-old who admits she has a hard time remembering to take the Pill, but says she wants to avoid unintended pregnancy. When you begin to counsel on the injectable contraceptive Depo Provera [depot medroxyprogesterone acetate (DMPA), Pfizer, New York City], what do you tell her about the drug?